Cargando…

Broad-spectrum anti-HIV activity and high drug resistance barrier of lipopeptide HIV fusion inhibitor LP-19

Lipopeptide-19, a HIV fusion inhibitor (LP-19), has showed potent anti-HIV activity. However, there is still limited information of the antiviral activity against different subtype clinical isolates and the drug resistance barrier of LP-19. Therefore, 47 HIV clinical isolates were selected for this...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Lin, Wang, Chen, Zhang, Yuanyuan, Chong, Huihui, Hu, Xiaoyan, Li, Dan, Xing, Hui, He, Yuxian, Shao, Yiming, Hong, Kunxue, Ma, Liying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225588/ https://www.ncbi.nlm.nih.gov/pubmed/37256122 http://dx.doi.org/10.3389/fimmu.2023.1199938

Ejemplares similares

In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to LP-40, Enfuvirtide-Based Lipopeptide Inhibitor
por: Hu, Yue, et al.
Publicado: (2022)

SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses
por: Zhu, Yuanmei, et al.
Publicado: (2021)

Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques
por: Chong, Huihui, et al.
Publicado: (2019)

Characteristics of Envelope Genes in a Chinese Chronically HIV-1 Infected Patient With Broadly Neutralizing Activity
por: Zhang, Dai, et al.
Publicado: (2019)

Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides
por: Zhu, Yuanmei, et al.
Publicado: (2022)

Biophysical Property and Broad Anti-HIV Activity of Albuvirtide, a 3-Maleimimidopropionic Acid-Modified Peptide Fusion Inhibitor
por: Chong, Huihui, et al.
Publicado: (2012)

Virus Evolution and Neutralization Sensitivity in an HIV-1 Subtype B′ Infected Plasma Donor with Broadly Neutralizing Activity
por: Hu, Yuanyuan, et al.
Publicado: (2021)

SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron
por: Zhu, Yuanmei, et al.
Publicado: (2022)

Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus
por: Yu, Danwei, et al.
Publicado: (2021)

Two M-T hook residues greatly improve the antiviral activity and resistance profile of the HIV-1 fusion inhibitor SC29EK
por: Chong, Huihui, et al.
Publicado: (2014)

A dePEGylated Lipopeptide-Based Pan-Coronavirus Fusion Inhibitor Exhibits Potent and Broad-Spectrum Anti-HIV-1 Activity without Eliciting Anti-PEG Antibodies
por: Xu, Ling, et al.
Publicado: (2023)

A broad-spectrum bactericidal lipopeptide with anti-biofilm properties
por: Meir, Ohad, et al.
Publicado: (2017)

Protocol for evaluating CD8(+) T cell-mediated immunity in latently SHIV-infected rhesus macaques with HIV fusion-inhibitory lipopeptide monotherapy
por: Sun, Yuting, et al.
Publicado: (2022)

Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants
por: Yu, Danwei, et al.
Publicado: (2021)

Long-Acting HIV-1 Fusion Inhibitory Peptides and their Mechanisms of Action
por: Wang, Chen, et al.
Publicado: (2019)

Epitope Mapping of M36, a Human Antibody Domain with Potent and Broad HIV-1 Inhibitory Activity
por: Wan, Chao, et al.
Publicado: (2013)

Gut Bacteria of Rattus rattus (Rat) Produce Broad-Spectrum Antibacterial Lipopeptides
por: Akbar, Noor, et al.
Publicado: (2021)

Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy
por: Chen, Yue, et al.
Publicado: (2021)

Identification of a novel HIV-1-neutralizing antibody from a CRF07_BC-infected Chinese donor
por: Sun, Youxiang, et al.
Publicado: (2017)

Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket
por: Zhang, Xiujuan, et al.
Publicado: (2018)

Preparation and evaluation of amphipathic lipopeptide‐loaded PLGA microspheres as sustained‐release system for AIDS prevention
por: Jin, Huijuan, et al.
Publicado: (2020)

Structural and Functional Characterization of the Secondary Mutation N126K Selected by Various HIV-1 Fusion Inhibitors
por: Yu, Danwei, et al.
Publicado: (2020)

Vaccination with dendritic cells loaded with HIV-1 lipopeptides elicits broad T cell immunity and control of viral load in HIV infected patients
por: Levy, Y, et al.
Publicado: (2012)

Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors
por: Geng, Xiuzhu, et al.
Publicado: (2019)

Design of a Bispecific HIV Entry Inhibitor Targeting the Cell Receptor CD4 and Viral Fusion Protein Gp41
por: Yan, Hongxia, et al.
Publicado: (2022)

Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection
por: Lan, Qiaoshuai, et al.
Publicado: (2021)

Development of novel broad-spectrum antimicrobial lipopeptides derived from plantaricin NC8 β
por: Wiman, Emanuel, et al.
Publicado: (2023)

The effects of HIV Tat DNA on regulating the immune response of HIV DNA vaccine in mice
por: Liu, Ye, et al.
Publicado: (2013)

Generation of HIV-resistant cells with a single-domain antibody: implications for HIV-1 gene therapy
por: Jin, Hongliang, et al.
Publicado: (2021)

Co-receptor usage and prediction of v3 genotyping algorithms in hiv-1 subtype b' from paid blood donors experienced anti-retroviral therapy in chinese central province
por: Qu, Shuiling, et al.
Publicado: (2010)

Genome Sequences of a Novel HIV-1 Circulating Recombinant Form (CRF61_BC) Identified among Heterosexuals in China
por: Li, Xingguang, et al.
Publicado: (2013)

De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery
por: Wang, Chao, et al.
Publicado: (2018)

Lp-PLA2 levels in HIV-infected patients
por: Díaz-Pollán, Beatriz, et al.
Publicado: (2014)

A Comprehensive Mapping of HIV-1 Genotypes in Various Risk Groups and Regions across China Based on a Nationwide Molecular Epidemiologic Survey
por: He, Xiang, et al.
Publicado: (2012)

Neutralization sensitivity of HIV-1 subtype B’ clinical isolates from former plasma donors in China
por: OuYang, Yabo, et al.
Publicado: (2013)

Escape from humoral immunity is associated with treatment failure in HIV-1-infected patients receiving long-term antiretroviral therapy
por: Ouyang, Yabo, et al.
Publicado: (2017)

Profiling the neutralizing antibody response in chronically HIV-1 CRF07_BC-infected intravenous drug users naïve to antiretroviral therapy
por: Hu, Xintao, et al.
Publicado: (2017)

Broad-spectrum antivirals against viral fusion
por: Vigant, Frederic, et al.
Publicado: (2015)

Enfuvirtide−PEG conjugate: A potent HIV fusion inhibitor with improved pharmacokinetic properties
por: Cheng, Shuihong, et al.
Publicado: (2016)

Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity
por: Zhu, Yuanmei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ga7dkpu2ro5i0c5oefgoql4qo5